Biomarkers of targeted therapy and immuno-oncology in cancers metastatic to the breast

Semir Vranic, Wijendra Senarathne, Phillip Stafford, Kelsey Poorman, Barbara A Pockaj, Zoran Gatalica

Research output: Contribution to journalArticle

Abstract

The breast is a rare site for metastases, and their molecular characteristics have not been studied yet. Intrinsic molecular genetics, cancer characteristics, and breast tissue immune responses in diverse metastases to the breast have not been previously studied. We identified 64 patients with cancers metastatic to the breast: 51 carcinomas and 13 melanomas. Programmed death ligand 1 (PD-L1), steroid receptors, and HER2/neu expressions were evaluated using immunohistochemistry. Gene sequencing, copy number alterations, microsatellite instability, and tumor mutational burden were performed using next-generation sequencing platforms. The 3 most common primary sites for metastatic carcinomas were lung (37%), ovary (29%), and fallopian tubes/peritoneum (14%). TP53 mutations were commonly (50%) observed among the carcinoma cases, while other mutations were characteristic for the primary cancers (VHL in renal, BRCA1 in the fallopian tube, and BRAF in melanomas). High tumor mutational burden was detected in 5/14 carcinomas and 3/7 melanomas. Tumor cell PD-L1 expression was detected in 6 carcinomas, but not in any of the melanomas, whereas immune cells' expression of PD-L1 was seen in 17 carcinomas and 6 melanomas. Estrogen receptor status was positive in 13/49 carcinomas including 12 adenocarcinomas originating from the ovary and fallopian tube or peritoneum and 1 duodenal neuroendocrine carcinoma. No carcinoma was HER2/neu positive. Intrinsic genetic characteristics of the metastases to the breast followed the pattern commonly seen in primary tumors. Biomarkers of potential benefit to immune checkpoint inhibition therapy were limited to PD-L1-positive non-small cell lung cancer. No common characteristics of the heterogeneous group of tumor metastases to this organ were identified.

Original languageEnglish (US)
JournalApplied Immunohistochemistry and Molecular Morphology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Breast
Biomarkers
Carcinoma
Melanoma
Fallopian Tubes
Neoplasms
Neoplasm Metastasis
Ligands
Peritoneum
Tumor Burden
Therapeutics
Ovary
Breast Neoplasms
Neuroendocrine Carcinoma
Microsatellite Instability
Mutation
Gene Dosage
Steroid Receptors
Non-Small Cell Lung Carcinoma
Estrogen Receptors

Keywords

  • breast
  • carcinoma
  • immuno-oncology
  • metastasis
  • molecular profiling
  • secondary cancers

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Medical Laboratory Technology

Cite this

Biomarkers of targeted therapy and immuno-oncology in cancers metastatic to the breast. / Vranic, Semir; Senarathne, Wijendra; Stafford, Phillip; Poorman, Kelsey; Pockaj, Barbara A; Gatalica, Zoran.

In: Applied Immunohistochemistry and Molecular Morphology, 01.01.2019.

Research output: Contribution to journalArticle

Vranic, Semir ; Senarathne, Wijendra ; Stafford, Phillip ; Poorman, Kelsey ; Pockaj, Barbara A ; Gatalica, Zoran. / Biomarkers of targeted therapy and immuno-oncology in cancers metastatic to the breast. In: Applied Immunohistochemistry and Molecular Morphology. 2019.
@article{9c418813ab2c41bd923ba0fcc0fd67cd,
title = "Biomarkers of targeted therapy and immuno-oncology in cancers metastatic to the breast",
abstract = "The breast is a rare site for metastases, and their molecular characteristics have not been studied yet. Intrinsic molecular genetics, cancer characteristics, and breast tissue immune responses in diverse metastases to the breast have not been previously studied. We identified 64 patients with cancers metastatic to the breast: 51 carcinomas and 13 melanomas. Programmed death ligand 1 (PD-L1), steroid receptors, and HER2/neu expressions were evaluated using immunohistochemistry. Gene sequencing, copy number alterations, microsatellite instability, and tumor mutational burden were performed using next-generation sequencing platforms. The 3 most common primary sites for metastatic carcinomas were lung (37{\%}), ovary (29{\%}), and fallopian tubes/peritoneum (14{\%}). TP53 mutations were commonly (50{\%}) observed among the carcinoma cases, while other mutations were characteristic for the primary cancers (VHL in renal, BRCA1 in the fallopian tube, and BRAF in melanomas). High tumor mutational burden was detected in 5/14 carcinomas and 3/7 melanomas. Tumor cell PD-L1 expression was detected in 6 carcinomas, but not in any of the melanomas, whereas immune cells' expression of PD-L1 was seen in 17 carcinomas and 6 melanomas. Estrogen receptor status was positive in 13/49 carcinomas including 12 adenocarcinomas originating from the ovary and fallopian tube or peritoneum and 1 duodenal neuroendocrine carcinoma. No carcinoma was HER2/neu positive. Intrinsic genetic characteristics of the metastases to the breast followed the pattern commonly seen in primary tumors. Biomarkers of potential benefit to immune checkpoint inhibition therapy were limited to PD-L1-positive non-small cell lung cancer. No common characteristics of the heterogeneous group of tumor metastases to this organ were identified.",
keywords = "breast, carcinoma, immuno-oncology, metastasis, molecular profiling, secondary cancers",
author = "Semir Vranic and Wijendra Senarathne and Phillip Stafford and Kelsey Poorman and Pockaj, {Barbara A} and Zoran Gatalica",
year = "2019",
month = "1",
day = "1",
doi = "10.1097/PAI.0000000000000808",
language = "English (US)",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Biomarkers of targeted therapy and immuno-oncology in cancers metastatic to the breast

AU - Vranic, Semir

AU - Senarathne, Wijendra

AU - Stafford, Phillip

AU - Poorman, Kelsey

AU - Pockaj, Barbara A

AU - Gatalica, Zoran

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The breast is a rare site for metastases, and their molecular characteristics have not been studied yet. Intrinsic molecular genetics, cancer characteristics, and breast tissue immune responses in diverse metastases to the breast have not been previously studied. We identified 64 patients with cancers metastatic to the breast: 51 carcinomas and 13 melanomas. Programmed death ligand 1 (PD-L1), steroid receptors, and HER2/neu expressions were evaluated using immunohistochemistry. Gene sequencing, copy number alterations, microsatellite instability, and tumor mutational burden were performed using next-generation sequencing platforms. The 3 most common primary sites for metastatic carcinomas were lung (37%), ovary (29%), and fallopian tubes/peritoneum (14%). TP53 mutations were commonly (50%) observed among the carcinoma cases, while other mutations were characteristic for the primary cancers (VHL in renal, BRCA1 in the fallopian tube, and BRAF in melanomas). High tumor mutational burden was detected in 5/14 carcinomas and 3/7 melanomas. Tumor cell PD-L1 expression was detected in 6 carcinomas, but not in any of the melanomas, whereas immune cells' expression of PD-L1 was seen in 17 carcinomas and 6 melanomas. Estrogen receptor status was positive in 13/49 carcinomas including 12 adenocarcinomas originating from the ovary and fallopian tube or peritoneum and 1 duodenal neuroendocrine carcinoma. No carcinoma was HER2/neu positive. Intrinsic genetic characteristics of the metastases to the breast followed the pattern commonly seen in primary tumors. Biomarkers of potential benefit to immune checkpoint inhibition therapy were limited to PD-L1-positive non-small cell lung cancer. No common characteristics of the heterogeneous group of tumor metastases to this organ were identified.

AB - The breast is a rare site for metastases, and their molecular characteristics have not been studied yet. Intrinsic molecular genetics, cancer characteristics, and breast tissue immune responses in diverse metastases to the breast have not been previously studied. We identified 64 patients with cancers metastatic to the breast: 51 carcinomas and 13 melanomas. Programmed death ligand 1 (PD-L1), steroid receptors, and HER2/neu expressions were evaluated using immunohistochemistry. Gene sequencing, copy number alterations, microsatellite instability, and tumor mutational burden were performed using next-generation sequencing platforms. The 3 most common primary sites for metastatic carcinomas were lung (37%), ovary (29%), and fallopian tubes/peritoneum (14%). TP53 mutations were commonly (50%) observed among the carcinoma cases, while other mutations were characteristic for the primary cancers (VHL in renal, BRCA1 in the fallopian tube, and BRAF in melanomas). High tumor mutational burden was detected in 5/14 carcinomas and 3/7 melanomas. Tumor cell PD-L1 expression was detected in 6 carcinomas, but not in any of the melanomas, whereas immune cells' expression of PD-L1 was seen in 17 carcinomas and 6 melanomas. Estrogen receptor status was positive in 13/49 carcinomas including 12 adenocarcinomas originating from the ovary and fallopian tube or peritoneum and 1 duodenal neuroendocrine carcinoma. No carcinoma was HER2/neu positive. Intrinsic genetic characteristics of the metastases to the breast followed the pattern commonly seen in primary tumors. Biomarkers of potential benefit to immune checkpoint inhibition therapy were limited to PD-L1-positive non-small cell lung cancer. No common characteristics of the heterogeneous group of tumor metastases to this organ were identified.

KW - breast

KW - carcinoma

KW - immuno-oncology

KW - metastasis

KW - molecular profiling

KW - secondary cancers

UR - http://www.scopus.com/inward/record.url?scp=85072318757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072318757&partnerID=8YFLogxK

U2 - 10.1097/PAI.0000000000000808

DO - 10.1097/PAI.0000000000000808

M3 - Article

C2 - 31517642

AN - SCOPUS:85072318757

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

ER -